Vaccinex Amends 8-K, Confirms Nasdaq Listing for VCNX Common Stock
Ticker: VCNX · Form: 8-K/A · Filed: Feb 8, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K/A |
| Filed Date | Feb 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: amendment, corporate-governance, exchange-listing
TL;DR
**Vaccinex filed an 8-K/A, confirming VCNX common stock is still listed on Nasdaq.**
AI Summary
Vaccinex, Inc. filed an amended 8-K/A on February 8, 2024, clarifying its previous 8-K filing from February 6, 2024. This amendment primarily updates the company's registration details, confirming its Common Stock, par value $0.0001 per share, is traded under the symbol VCNX on the Nasdaq Capital Market. This matters to investors as it reaffirms the company's listing status and provides updated administrative information, ensuring transparency regarding its publicly traded securities.
Why It Matters
This filing provides updated administrative information, confirming Vaccinex's listing on the Nasdaq Capital Market, which is crucial for investors tracking the company's stock.
Risk Assessment
Risk Level: low — This filing is an administrative amendment and does not introduce new financial or operational risks to the company.
Analyst Insight
Investors should note this administrative update confirms Vaccinex's continued listing on Nasdaq, but it doesn't provide new information to change investment decisions. It's a routine compliance filing.
Key Numbers
- $0.0001 — Par Value per Share (The stated par value of Vaccinex's Common Stock.)
Key Players & Entities
- VACCINEX, INC. (company) — the registrant filing the 8-K/A
- Nasdaq Capital Market (company) — the exchange where Vaccinex's common stock is registered
- VCNX (company) — the trading symbol for Vaccinex's common stock
- $0.0001 (dollar_amount) — the par value per share of Vaccinex's Common Stock
- February 6, 2024 (date) — the date of the earliest event reported in the original 8-K
FAQ
What is the purpose of this 8-K/A filing by Vaccinex, Inc.?
This 8-K/A filing is an amendment to a previous 8-K, primarily to provide updated information regarding the company's registration details, specifically confirming its Common Stock is registered on the Nasdaq Capital Market under the trading symbol VCNX.
On what date was the earliest event reported in the original 8-K that this amendment refers to?
The earliest event reported in the original 8-K was on February 6, 2024, as stated in the filing: "Date of Report (Date of earliest event reported): February 6, 2024."
What is the trading symbol and the exchange where Vaccinex, Inc.'s Common Stock is registered?
Vaccinex, Inc.'s Common Stock is registered under the trading symbol VCNX on the Nasdaq Capital Market, as indicated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the par value per share of Vaccinex, Inc.'s Common Stock?
The par value per share of Vaccinex, Inc.'s Common Stock is $0.0001, as specified in the filing: "Common Stock, par value $0.0001 per share."
What is Vaccinex, Inc.'s business address and phone number?
Vaccinex, Inc.'s business address is 1895 Mount Hope Avenue, Rochester, New York, 14620, and its telephone number is (585) 271-2700, as listed under 'BUSINESS ADDRESS' and 'Registrant’s telephone number' in the filing.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-02-08 08:20:53
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
Filing Documents
- d774086d8ka.htm (8-K/A) — 26KB
- d774086dex42.htm (EX-4.2) — 90KB
- 0001193125-24-027618.txt ( ) — 267KB
- vcnx-20240206.xsd (EX-101.SCH) — 3KB
- vcnx-20240206_lab.xml (EX-101.LAB) — 18KB
- vcnx-20240206_pre.xml (EX-101.PRE) — 11KB
- d774086d8ka_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. The following exhibits are filed herewith: Exhibit Number Exhibit Description 4.1* Form of Pre-Funded Warrant 4.2 Form of Common Warrant 10.1* Securities Purchase Agreement by and between the Company and the Investors, dated as of February 6, 2024 10.2* Registration Rights Agreement by and between the Company and the Investors, dated as of February 7, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Previously filed 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Vaccinex, Inc. Date: February 8, 2024 By: /s/ Scott E. Royer Scott E. Royer Chief Financial Officer